Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial

Samir S. Taneja

doi:10.1016/j.juro.2016.07.067

Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial

Samir S. Taneja

Biomedical Engineering

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	1124-1125
Number of pages	2
Journal	The Journal of urology
Volume	196
Issue number	4
DOIs	https://doi.org/10.1016/j.juro.2016.07.067
State	Published - Oct 1 2016

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2016.07.067

Cite this

Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. / Taneja, Samir S.
In: The Journal of urology, Vol. 196, No. 4, 01.10.2016, p. 1124-1125.

Research output: Contribution to journal › Comment/debate › peer-review

@article{98deb504ee4d4daf8cf4b3394753baeb,

title = "Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial",

author = "Taneja, {Samir S.}",

year = "2016",

month = oct,

day = "1",

doi = "10.1016/j.juro.2016.07.067",

language = "English (US)",

volume = "196",

pages = "1124--1125",

journal = "The Journal of urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Re

T2 - Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial

AU - Taneja, Samir S.

PY - 2016/10/1

Y1 - 2016/10/1

UR - http://www.scopus.com/inward/record.url?scp=85050654433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050654433&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2016.07.067

DO - 10.1016/j.juro.2016.07.067

M3 - Comment/debate

C2 - 27628795

AN - SCOPUS:85050654433

SN - 0022-5347

VL - 196

SP - 1124

EP - 1125

JO - The Journal of urology

JF - The Journal of urology

IS - 4

ER -

Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this